Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats

References

• Abbott NJ, Rönnbäck L, Hansson E. (2006). Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 7:41–53
   PubMed Web of Science ®Google Scholar
• Agarwal S, Sane R, Gallardo JL, et al. (2010). Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147–55
   PubMed Web of Science ®Google Scholar
• Bundgaard C, Jensen CJ, Garmer M. (2012). Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice. Drug Metab Dispos 40:461–6
   PubMedGoogle Scholar
• Chu X, Zhang Z, Yabut J, et al. (2012). Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases. Mol Pharmacol 81:220–7
   PubMed Web of Science ®Google Scholar
• Dahlin A, Geier E, Stocker SL, et al. (2013). Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm 10:650–63
   PubMedGoogle Scholar
• Doran A, Obach RS, Smith BJ, et al. (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1a/1b knockout mouse model. Drug Metab Dispos 33:165–74
   PubMed Web of Science ®Google Scholar
• Enokizono J, Kusuhara H, Ose A, et al. (2008). Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36:995–1002
   PubMed Web of Science ®Google Scholar
• Fuchs H, Kishimoto W, Gansser D, et al. (2014). Brain penetration of WEB 2086 (apafant) and dantrolene in Mdr1a (P-gp) and Bcrp Knockout Rats. Drug Metab Dispos 42:1761–5
   PubMedGoogle Scholar
• Gazzin S, Strazielle N, Schmitt C, et al. (2008). Differential expression of the multidrug resistance related proteins ABCb1 and ABCc1 between blood–brain interfaces. J Comp Neurol 510:497–507
   PubMed Web of Science ®Google Scholar
• Gerhart DZ, Drewes LR. (1990). Glucose transporters at the blood-nerve barrier are associated with perineurial cells and endoneurial microvessels. Brain Res 508:46–50
   PubMedGoogle Scholar
• Huang L, Be X, Tchaparian EH, et al. (2012). Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats. J Pharmacol Exp Ther 343:316–24
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS. (2002). Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–38
   PubMed Web of Science ®Google Scholar
• Keep RF, Smith DE. (2011). Choroid plexus transport: gene deletion studies. Fluids Barriers CNS 8:26–35
   PubMedGoogle Scholar
• Kim RB, Fromm MF, Wandel C, et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–94
   PubMed Web of Science ®Google Scholar
• Kodaira H, Kusuhara H, Fujita T, et al. (2011). Quantitative evaluation of the impact of active efflux by P-glycoprotein and breast cancer resistance protein at the blood–brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 339:935–44
   PubMed Web of Science ®Google Scholar
• Leggas M, Adachi M, Scheffer GL, et al. (2004). Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612–21
   PubMed Web of Science ®Google Scholar
• Lin JH. (2008). CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 9:46–59
   PubMed Web of Science ®Google Scholar
• Liu X, Cheong J, Ding X, Deshmukh G. (2014). Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebral spinal fluid concentrations in wild-type and p-glycoprotein knockout rats. Drug Metab Dispos 42:482–91
   PubMedGoogle Scholar
• Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. (2012). Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342:33–40
   PubMed Web of Science ®Google Scholar
• Oberoi RK, Mittapalli RK, Elmquist WF. (2013). Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther 347:755–64
   PubMed Web of Science ®Google Scholar
• Ohno K, Pettigrew KD, Rapoport SI. (1978). Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235:H299–307
   PubMed Web of Science ®Google Scholar
• Polli JW, Jarrett JL, Studenberg SD, et al. (1999). Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206–12
   PubMed Web of Science ®Google Scholar
• Polli JW, Olson KL, Chism JP, et al. (2009). An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439–42
   PubMed Web of Science ®Google Scholar
• Rao VV, Dahlheimer JL, Bardgett ME, et al. (1999). Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood–cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 96:3900–5
   PubMed Web of Science ®Google Scholar
• Rechthand E, Rapoport S. (1987). Regulation of the microenvironment of peripheral nerve: role of the blood-nerve barrier. Prog Neurobiol 28:303–43
   PubMed Web of Science ®Google Scholar
• Rechthand E, Smith QR, Rapoport SI. (1989). Structural specificity of sugar transport at the blood-nerve barrier. J Neurochem 53:119–23
   PubMedGoogle Scholar
• Schinkel AH, Smit JJ, van Tellingen O, et al. (1994). Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77:491–502
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–24
   PubMed Web of Science ®Google Scholar
• Shen J, Carcaboso AM, Hubbard KE, et al. (2009). Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 69:5885–92
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Hayashida T, Hamada A, et al. (2014). Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants. J Acquir Immune Defic Syndr 66:484–6
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. (2011). Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579–88
   PubMed Web of Science ®Google Scholar
• Wadhwani KC, Smith QR, Rapoport SI. (1990). Facilitated transport of L-phenylalanine across blood-nerve barrier of rat peripheral nerve. Am J Physiol 258:R1436–44
   PubMedGoogle Scholar
• Weerasuriya A, Mizisin AP. (2011). The blood–nerve barrier: structure and functional significance. Methods Mol Biol 686:149–73
   PubMedGoogle Scholar
• Wijnholds J, deLange EC, Scheffer GL, et al. (2000). Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood–cerebrospinal fluid barrier. J Clin Invest 105:279–85
   PubMed Web of Science ®Google Scholar
• Xiao G, Black C, Hetu G, et al. (2012). Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos 40:779–87
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. (2012). Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos 40:1825–33
   PubMed Web of Science ®Google Scholar
• Zhou L, Schmidt K, Nelson FR, et al. (2009). The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (imatinib), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37:946–55
   PubMed Web of Science ®Google Scholar